Tuna fısh may carry bacteria that, even at lowered temperatures, grow and retain histidine decarboxylase (HDC) enzyme activity, raising questions about the potential for those enzymes producing histamines in refrigerated fresh tuna, according to Kristin Björn-sdóttir-Butler, of the Gulf Coast Seafood Laboratory, a Food and Drug Administration research facility on Dauphin Island, Ala., and her collaborators. These cold-tolerant, histamineproducing bacteria are indigenous to the fısh, not contaminants introduced during handling, the researchers note. Details appeared 29 January 2016 in Applied and Environmental Microbiology (doi:10.1128/AEM.02833-15/) .
Björnsdóttir-Butler and her collaborators used swabs to obtain samples from gills, skin, and anal vents of yellowfın, skipjack, and albacore tuna. Swabs from the anal vents contained Photobacterium angustum and Photobacterium kishitanii bacteria among other species, she says. Unexpectedly, these bacteria can grow at 5 o C (41 o F) as well as at higher temperatures. Moreover, both these species carry and express the histidine decarboxylase gene, which is necessary for producing histamine. However, not all members of these fısh-associated bacterial species carry the histidine decarboxylase gene; nor is it known whether the gene is plasmid-or chromosome-based, according to the report. P. kishitanii are better known because of their affıliation with deep-water fısh species in which they form symbioses within the light organs of their hosts, enabling them to be bioluminescent in exchange for nutrients and travel privileges. The presence of these bacteria in tuna is likely due to the fısh feeding on other fınned fısh with such light organs or, alternatively, on those crustaceans and squid that may carry Photobacterium species, according to Björnsdóttir-Butler and her collaborators. The presence of these Photobacterium species in freshly caught tuna indicates that they are indigenous to the tuna and not present as a result of postharvest contamination during handling and processing of the fısh, she points out. Scombroid fısh, such as tuna and mackerel, and some other fınned fısh species, such as mahi-mahi, are more likely than other fısh to accumulate histamine because they carry high levels of histidine in their muscle tissues.
Although histamine poisoning from fısh is well known, the potential for its production by fısh-associated bacteria at low temperatures is a new fınding, suggesting seafood safety experts should now take this possibility into account, according to William Fenical of the Scripps Institution of Oceanography in La Jolla, Calif., who was not involved in the research. "Histamine is not a toxin per se," he says, explaining that it does not block sodium channels, nerve transmission, or similarly vital functions. Even so, he adds, the industry takes the risk of scombroid fısh-associated histamine "rather casually." Its effects when ingested are similar to those of an allergic reaction in terms of symptoms and mechanism. Indeed, histamine is the same compound that, Tuna, a major food fish, harbor indigenons cold-tolerant, histamine-producing bacteria that can produce reactions in those who consume them. (Image © iStockphoto/GuidoMontaldo.) when produced endogenously, triggers allergic reactions. "You can get sick, but it would be diffıcult to die from it unless you are prone to anaphylactic shock," he says.
In contrast, shellfısh poisoning is much more virulent for those who dine on contaminated servings of it, Fenical continues. Typically, the toxins associated with shellfısh are complex organic chemicals produced by dinoflagellates, diatoms, or other phytoplankton that shellfısh accumulate via fılter feeding.
David Holzman is a freelance writer in Lexington, Mass.
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Repurposing Drugs, and Fresh Outcomes from Other Familiar Sources Jeffrey L. Fox
In the face of new and emerging infectious disease threats, it is prudent to look back at old or even ancient sources to uncover a drug or entity that might work anew or in a different context, according to several researchers who spoke during the 2016 ASM Biodefense and Emerging Diseases Research Meeting last February. Here, let us consider the old in three specifıc ways: revisiting licensed drugs, using old phage for new purposes, and looking at old beasts for new antimicrobials.
Inspired in part by a 2014 National Academy of Sciences workshop report, Rob Davey of the Texas Biomedical Research Institute in San Antonio and his collaborators examined many kinds of approved drugs, looking for any with activity against Ebola virus that might be "repurposed" as antiviral agents. A broad drug-repurposing effort sponsored by the Defense Threat Reduction Agency targeting this virus traces back even earlier to 2006, Davey says. This strategy seeks to curb the "huge failure rate" everyone faces in developing drugs from scratch, only 5% of which ever make it to clinical trials, and still more of which fail from that point onward, he notes.
In practice, however, teaching old drugs to perform new tricks is not so easy, Davey continues. First, there are no libraries from which to check out a Food and Drug Administration (FDA)-approved set of approximately 4,000 chemical entities bearing the agency stamp of approval. Furthermore, about half the companies he contacted "don't want their drugs retested, and that's a big issue because they're worried you'll discover something 'funny' or adverse," he says. On the plus side, among those FDA-approved drugs that companies agree to subject to retesting, the hit rate is "15-fold higher than it is with randomly selected compounds."
Although various repurposed drugs show activity against the Ebola virus, many do so at concentrations that would not be healthy for the human taking them, according to Davey. Even some more promising candidates from among channel-blocking drugs proved unworkable, however, because not only are they potentially lethal for the host but they also do not block the right viral target, he says. Yet another channel blocker, although potent against the Ebola virus when used in nanomolar concentrations, requires further tinkering because of its hypotensive activity, Davey says. "Can we separate its blood-pressure-lowering activity from its Ebola activity, and optimize the latter?" Moreover, the underlying mechanism for its viral-killing activity is "still a bit of a mystery," he adds. Although some
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Recent developments involving microbiology and related science policy matters include:
• Late in February, the U.S. Senate confirmed Robert Califf to be Commissioner of the U.S. Food and Drug Administration (FDA).
• Senator Al Franken (D-MN) introduced a bill (S. 2512) in February that would add Zika virus to the FDA priority review voucher program, providing further incentives for companies to develop drugs or biologics targeting this virus.
• Several members of Congress in February formally requested the federal Office of Management and Budget to reassign "unobligated funds" for studying Ebola virus to support research on Zika virus instead.
• FDA officials in February said that they would exercise "enforcement discretion" regarding investigational new drug requirements for the use of fecal microbiota for transplantation (FMT) to treat patients infected with Clostridium difficile. The agency stipulated that patients must consent to such treatment, the FMT product to be used is "not obtained from a stool bank," and FMT donors and products be subject to "screening and testing." • The peer-review process followed by the National Institutes of Health and other federal agencies "is not necessarily funding the best science" and awarding grants by lottery could "result in equally good, if not better, results," say Ferric Fang, at the University of Washington, Anthony Bowen at the Albert Einstein College of Medicine, and Arturo Casadevall at the Johns Hopkins Bloomberg School of Public Health. Peer review can be effective when discriminating "between very good science and very bad science," according to their analysis, which evaluates research in terms of how often it is cited once published. Details appeared 16 February 2016 in eLife (doi: http://dx.doi.org/10.7554/eLife.13323).
